Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth-Tetracycline-Rabeprazole Triple vs Bismuth Quadruple Therapies for First-Line Eradication of Helicobacter Pylori
NCT07788053Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Randomised trial of tetracycline in Helicobacter pylori infection (2 arms). Primary endpoint: Helicobacter pylori eradication rate at 6 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07788053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788053.